Imagine cells adorned with intricate "sugar coats" — not merely as identification tags, but as complex communication codes. In this elaborate glycan universe, fucose emerges as a pivotal player. This methylated sugar participates in cellular recognition, inflammatory responses, and holds profound implications in tumor metastasis and genetic disorders. Today, we delve into fucose's biological significance and its untapped potential in life sciences and medicine.
Though present in modest quantities within glycoproteins, glycolipids, and gangliosides, fucose's structural positioning renders it indispensable. During cellular turnover, proteases cleave protein moieties from glycoproteins, leaving behind oligosaccharide chains of remarkable complexity — some comprising up to 27 sugar residues. Fucose invariably occupies terminal positions on these chains, requiring α-fucosidase-mediated removal for further degradation. These components constitute the bulk of oligosaccharides accumulating in lysosomes and excreted in fucosidosis patients' urine, with over 20 distinct fucose-containing metabolites identified to date.
Sphingolipids decorated with fucose — including blood group antigens A, B, H, and Lewis systems — also accumulate in fucosidosis. Surprisingly, initial hypotheses linking disease severity to blood type remain unvalidated. Meanwhile, fucosylated gangliosides, though minor tissue constituents, have been isolated from human cataracts (seven variants) and brain tissue (one variant). Keratan sulfate stands unique among glycosaminoglycans by incorporating α-fucose, with levels quintupling in certain patients.
Fucose achieves biological prominence as the critical ligand for selectins — lectin-family adhesion receptors expressed on platelets (P-selectin), endothelium (E/P-selectins), and leukocytes (L-selectin). These receptors recognize fucosylated glycans like sialyl-Lewis x , orchestrating systemic cell-cell interactions during inflammation, extravasation, and embryogenesis. Tumor biology reveals darker applications: malignant cells often overexpress fucosyltransferases (FucTs), with sialyl-Lewis x expression correlating strongly with metastatic potential.
Beyond glycan modifications, O-fucosylation directly targets protein hydroxyl groups within EGF-like repeats. The Notch receptor exemplifies this paradigm — its ligand-binding capacity strictly depends on fucosylation status, enabling extracellular signal transduction. The staggering diversity of fucosylated glycans, compounded by analytical challenges, leaves many biological functions obscure. Differential FucTs expression generates this structural variety, manifesting distinctly in cancer and inflammatory pathologies.
This sulfated, anionic polymer — rich in L-fucose — derives primarily from brown algae species like Fucus vesiculosus , Ascophyllum nodosum , and Laminaria japonica . Structural variations emerge across sources: while F. vesiculosus yields relatively simple L-fucose/sulfate polymers, other species incorporate D-mannose, D-galactose, uronic acids, and acetyl groups. The backbone typically features α-(1→3)-linked fucose units, occasionally alternating with α-(1→4) linkages, with O-2 branching and variable sulfation at O-2/O-4 positions. Molecular weights span 5–7 kDa to several hundred kDa, with lower-mass fractions demonstrating superior biocompatibility. Pharmacological studies reveal striking anti-thrombotic, anti-neoplastic, anti-viral, and anti-inflammatory properties.
Though radiolabeled fucose incorporation into brain glycoproteins was documented decades ago, neural fucosyltransferase expression remains poorly mapped. Ironically, among the earliest in vitro FucT activity reports came from murine brain microsomes, transferring 14 C-fucose from GDP-fucose to mucin-type glycoproteins via α1,2-linkages. Subsequent characterization of α1,3-FucT from embryonic chicken brain revealed its capacity to fucosylate internal GlcNAc on nLcOse4Cer. The functional implications of neural fucosylation — particularly in ganglioside biology — demand urgent exploration.
Fucosylation employs GDP-fucose as the activated donor, synthesized through cytosolic de novo (90% contribution) and salvage pathways. The de novo route converts GDP-mannose via GDP-mannose 4,6-dehydratase and GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase, while the salvage pathway phosphorylates free fucose before GDP conjugation. GDP-fucose translocates into Golgi via specific transporters, becoming FucTs' substrate. Thirteen human FUT genes encode these enzymes with remarkable specificity:
- FUT1/2: α-1,2-FucTs generating ABH blood group antigens
- FUT3-7,9-11: α-1,3-FucTs (FUT3/5 also exhibit α-1,4 activity)
- FUT8: Sole α-1,6-FucT mediating core N-glycan fucosylation
- POFUT1/2: O-fucosyltransferases modifying peptide backbones
FUT3's overexpression correlates with cancer progression, catalyzing Lewis antigen synthesis (Lewis a/b/x/y , sialyl-Lewis a/x ). FUT8's core fucosylation critically modulates receptor signaling, while POFUT1's Notch modification proves essential for development.
Water, dilute acid, or calcium chloride solutions extract this sulfated polysaccharide, followed by precipitation with lead/aluminum hydroxide, ethanol, or quaternary ammonium salts. Our comparative studies demonstrate hot-water extraction's industrial superiority for Laminaria japonica fucoidan. Chromatographic separation yields three fractions:
- Galactofucan sulfate: (1→3)-α-L-Fuc p backbone with C-4 (35%) or C-2 (65%) branching (β-D-Gal or Fuc termini respectively), sulfated at C-2/C-4
- Fucoglucuronomanan: Alternating GlcA(1→4)-Man(1→2) backbone, occasional C-6 sulfation
- Fucan sulfate: Simpler alternating (1→3)/(1→4)-α-L-Fuc p with C-2/C-3 sulfation
This structural diversity — influenced by algal species and extraction methods — underlies fucoidan's varied bioactivities. Brown algal fucoidans typically feature linear α-1,3/1,4-linked Fuc p chains with O-2/O-3 sulfation, occasionally acetylated or substituted with other sugars.
Unlike terminal N-glycan fucosylation, O-fucosylation attaches L-fucose directly to serine/threonine, often undergoing elongation. Early evidence emerged from human urine isolates — Thr-linked Glc(β1-3)Fuc(α1-O-) and simpler Fuc(α1-O-)Thr/Ser. Mass spectrometry later identified monofucosylated O-glycans on urokinase plasminogen activator (uPA), tissue plasminogen activator, and coagulation factors VII, IX, XII. Factor IX uniquely carries the tetrasaccharide Sia(α2-6)Gal(β1-4)GlcNAc(β1-3)Fuc(α1-O-)Ser.
These modifications occur exclusively within epidermal growth factor-like (EGF) repeats — 40-residue cysteine knot modules with conserved C1–C3, C2–C4, C5–C6 disulfides. Sequence analysis revealed the consensus C2-X-X-G-G-(S/T)-C3 (later revised to C2-X 4–5 -(S/T)-C3), predicting O-fucosylation sites in Notch, Delta, Jagged, and Cripto. CHO cell studies identified competing elongation pathways: β-1,3-glucosyltransferase versus β-1,3-N-acetylglucosaminyltransferase activities generating distinct O-fucose glycans.
